ClinicalTrials.gov posted results on 2026-08-11 for NCT03600701, a phase 2 study of atezolizumab plus cobimetinib in metastatic, recurrent, or refractory non-small cell lung cancer. The record listed 53 enrolled participants and remains active not recruiting.
Background
The trial studied patients with metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, refractory lung non-small cell carcinoma, and stage IV lung cancer AJCC v8. The posted brief summary says the study evaluated how well atezolizumab and cobimetinib work in this population.
Trial design
This was a phase 2 trial of atezolizumab and cobimetinib. The record lists 53 participants and includes two cohorts: Cohort 1 (KRAS Mutant) and Cohort 2 (KRAS Wild-type). The posted page does not provide a primary outcome section.
Key results
The results page reported 1 participant with a durable response in Cohort 1 (KRAS Mutant) and 2 participants with a durable response in Cohort 2 (KRAS Wild-type).
For other reported disease outcomes, the counts were 0 participants in both cohorts for one measure, 2 participants in both cohorts for another measure, 11 participants versus 8 participants for a third measure, and 7 participants versus 10 participants for a fourth measure.
What this means
The posted record adds outcome data for a small phase 2 lung cancer study of atezolizumab plus cobimetinib, with results split by KRAS mutation status. Because the page does not include the outcome definitions in the data block, the numbers are most useful as a source-linked trail for clinicians and researchers checking the registry entry directly.
Source
This information is based on ClinicalTrials.gov trial results for NCT03600701 posted on 2026-08-11. The record is available at clinicaltrials.gov.